First evaluation of a S100A8/S100A9-specific nanobody to assess phagocyte-driven inflammatory activity in a murine arthritis model in vivo

Wouter van den Heijden (AUMC)
Presentation: First evaluation of a S100A8/S100A9-specific nanobody to assess phagocyte-driven inflammatory activity in a murine arthritis model in vivo

With a strong focus on treatment evaluation, Wouter van den Heijden presented research on the role of imaging biomarkers in assessing therapeutic response. His work highlights how molecular imaging can offer early and detailed insights into how patients respond to treatment, enabling more precise adjustments to therapy. By improving the ability to monitor disease progression and treatment effectiveness, this research contributes to more targeted and efficient healthcare approaches, particularly within the field of immunotherapy.